Boehringer Ingelheim announces European Medicines Agency's filing acceptance and validation of marketing authorization application for spesolimab in generalized pustular psoriasis

The marketing authorization application (MAA) package includes results from the pivotal Effisayil-1 global trial Boehringer Ingelheim announced today that the company's marketing authorization

Related Keywords

,Boehringer Ingelheim ,Janine Lamar ,Julia Faass ,Corporate Communications ,European Medicines Agency ,Global Spesolimab Lead ,Boehringer ,Ingelheim ,Nnounces ,European ,Medicines ,Agency ,Filing ,Acceptance ,Validation ,Marketing ,Authorization ,Application ,Spesolimab ,Generalized ,Pustular ,Psoriasis ,